IL33 and breast cancer: In 4T1 breast cancer model mice, intraperitoneal administration of IL-33 promoted tumour angiogenesis through facilitating the intratumoural accumulation of immunosuppressive and innate lymphoid cells; this process was attenuated in ST2-deficient mice21.